Paper Details

  1. Home
  2. Paper Details

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

Author: AllisonDavid B, DayWesley W, GaddeKishore M, PetersonCraig A, RyanDonna H, SchwiersMichael L, TroupinBarbara

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Phentermine plus topiramate controlled-release combination was assessed for weight loss and metabolic risk reduction in individuals who were overweight and obese, with two or more risk factors.
Paper Details　
Original Abstract of the Article :
Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. We therefore assessed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct to diet and lifestyle ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(11)60205-5

データ提供：米国国立医学図書館（NLM）

CONQUER: A Randomized Trial Exploring Phentermine Plus Topiramate for Weight Loss and Metabolic Risk Reduction

Obesity, a desert of health challenges, affects millions worldwide. This study, like a camel caravan traversing a vast landscape, investigates the efficacy and safety of a combination medication, phentermine plus topiramate controlled-release, as a potential solution for weight loss and metabolic risk reduction. The researchers, like skilled navigators, meticulously designed a randomized, placebo-controlled, phase 3 trial, carefully following established scientific protocols. They found that this combination therapy can be a valuable tool in the fight against obesity.

Weighing the Benefits and Risks: A Balanced Approach

The study demonstrated that phentermine plus topiramate, when combined with diet and lifestyle changes, led to significant weight loss and improvements in metabolic risk factors in individuals who were overweight or obese. This is like discovering a hidden oasis in the desert, where individuals can find relief from the burdens of obesity and its associated health risks. However, it's important to remember that this medication is not a magic bullet and should be used in conjunction with other health-promoting strategies.

A Journey Towards Better Health

This research provides valuable insights into the potential of combination therapies in addressing obesity and its associated health complications. It offers a promising path toward achieving a healthier lifestyle and navigating the complex terrain of weight management. The study emphasizes the need for a balanced approach, combining medication with healthy habits and lifestyle changes, to effectively combat the challenges of obesity.

Dr.Camel's Conclusion

This study presents a promising oasis in the desert of obesity treatment. By combining the power of medication with the strength of lifestyle changes, individuals can potentially embark on a transformative journey towards a healthier and more fulfilling life.
Date :
  1. Date Completed 2011-04-28
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

21481449

DOI: Digital Object Identifier

10.1016/S0140-6736(11)60205-5

Related Literature

Article Analysis
・Effects of phentermine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.